CD274 and neoplasm: Several ICIs are now approved by the US Food and Drug Administration, including cytotoxic T-lymphocyte-associated protein-4, programmed death-1 (PD-1), and programmed death-ligand 1 (PD-L1) inhibitors, with indications across 19 different tumor types and two tissue-agnostic conditions [1].